113 related articles for article (PubMed ID: 37180703)
21. Aminobisphosphonate-treated ewes as a model of osteonecrosis of the jaw and of dental implant failure.
Davison MR; Lyardet L; Preliasco M; Yaful G; Torres P; Bonanno MS; Pellegrini GG; Zeni SN
J Periodontol; 2020 May; 91(5):628-637. PubMed ID: 31755105
[TBL] [Abstract][Full Text] [Related]
22. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).
Black DM; Reid IR; Boonen S; Bucci-Rechtweg C; Cauley JA; Cosman F; Cummings SR; Hue TF; Lippuner K; Lakatos P; Leung PC; Man Z; Martinez RL; Tan M; Ruzycky ME; Su G; Eastell R
J Bone Miner Res; 2012 Feb; 27(2):243-54. PubMed ID: 22161728
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and Safety of Oral Ibandronate versus Intravenous Zoledronic Acid on Bone Metabolism and Bone Mineral Density in Postmenopausal Japanese Women with Osteoporosis.
Uehara M; Nakamura Y; Suzuki T; Nakano M; Takahashi J
J Clin Med; 2021 Nov; 10(22):. PubMed ID: 34830702
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic efficacy of zoledronic acid combined with calcitriol in elderly patients receiving total hip arthroplasty or hemiarthroplasty for osteoporotic femoral neck fracture.
Zhu K; Zhang J; Zhang C; Zhao Z; Gao J; Li X; Xia X; Xu X; Zhang T; Guan J
Osteoporos Int; 2021 Mar; 32(3):559-564. PubMed ID: 32989470
[TBL] [Abstract][Full Text] [Related]
25. Radiodensitometric study for evaluation of bone mineral density around dental implants after zoledronic acid treatment in ovariectomized rats.
Dikicier S; Dikicier E; Karacayli U; Erguder B
Med Oral Patol Oral Cir Bucal; 2017 May; 22(3):e377-e382. PubMed ID: 28390131
[TBL] [Abstract][Full Text] [Related]
26. Development, in vitro and in vivo characterization of zoledronic acid functionalized hydroxyapatite nanoparticle based formulation for treatment of osteoporosis in animal model.
Khajuria DK; Razdan R; Mahapatra DR
Eur J Pharm Sci; 2015 Jan; 66():173-83. PubMed ID: 25444840
[TBL] [Abstract][Full Text] [Related]
27. Effect of systemic administered zoledronic acid on osseointegration of a titanium implant in ovariectomized rats.
Dikicier E; Karaçaylı Ü; Dikicier S; Günaydın Y
J Craniomaxillofac Surg; 2014 Oct; 42(7):1106-11. PubMed ID: 24530079
[TBL] [Abstract][Full Text] [Related]
28. Microcirculatory consequences of limb ischemia/reperfusion in ovariectomized rats treated with zoledronic acid.
Pócs L; Janovszky Á; Ocsovszki I; Kaszaki J; Piffkó J; Szabó A
J Orthop Surg Res; 2019 Apr; 14(1):95. PubMed ID: 30947735
[TBL] [Abstract][Full Text] [Related]
29. Effect of zoledronic acid on vertebral marrow adiposity in postmenopausal osteoporosis assessed by MR spectroscopy.
Yang Y; Luo X; Yan F; Jiang Z; Li Y; Fang C; Shen J
Skeletal Radiol; 2015 Oct; 44(10):1499-505. PubMed ID: 26130070
[TBL] [Abstract][Full Text] [Related]
30. The combination therapy with zoledronic Acid and propranolol improves the trabecular microarchitecture and mechanical property in an rat model of postmenopausal osteoporosis.
Khajuria DK; Razdan R; Mahapatra DR
J Osteoporos; 2014; 2014():586431. PubMed ID: 24800099
[TBL] [Abstract][Full Text] [Related]
31. Antiresorptive Agents are More Effective in Preventing Titanium Particle-Induced Calvarial Osteolysis in Ovariectomized Mice Than Anabolic Agents in Short-Term Administration.
Fu G; Li S; Ouyang N; Wu J; Li C; Liu W; Qiu J; Peng P; Qin L; Ding Y
Artif Organs; 2018 Sep; 42(9):E259-E271. PubMed ID: 30328628
[TBL] [Abstract][Full Text] [Related]
32. Treatment with zoledronic acid subsequent to odanacatib prevents bone loss in postmenopausal women with osteoporosis.
Koldkjær Sølling AS; Harsløf T; Langdahl B
Osteoporos Int; 2019 May; 30(5):995-1002. PubMed ID: 30656367
[TBL] [Abstract][Full Text] [Related]
33. Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis: A 2-Year Randomized Study.
Sølling AS; Harsløf T; Langdahl B
J Bone Miner Res; 2021 Jul; 36(7):1245-1254. PubMed ID: 33813753
[TBL] [Abstract][Full Text] [Related]
34. Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study.
Hadji P; Kauka A; Ziller M; Birkholz K; Baier M; Muth M; Bauer M
Osteoporos Int; 2014 Apr; 25(4):1369-78. PubMed ID: 24504100
[TBL] [Abstract][Full Text] [Related]
35. Puerarin improves OVX-induced osteoporosis by regulating phospholipid metabolism and biosynthesis of unsaturated fatty acids based on serum metabolomics.
Li B; Wang Y; Gong S; Yao W; Gao H; Liu M; Wei M
Phytomedicine; 2022 Jul; 102():154198. PubMed ID: 35636175
[TBL] [Abstract][Full Text] [Related]
36. Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial.
Llombart A; Frassoldati A; Paija O; Sleeboom HP; Jerusalem G; Mebis J; Deleu I; Miller J; Schenk N; Neven P
Clin Breast Cancer; 2012 Feb; 12(1):40-8. PubMed ID: 22014381
[TBL] [Abstract][Full Text] [Related]
37. Prior administration of vitamin K2 improves the therapeutic effects of zoledronic acid in ovariectomized rats by antagonizing zoledronic acid-induced inhibition of osteoblasts proliferation and mineralization.
Zhao B; Zhao W; Wang Y; Zhao Z; Zhao C; Wang S; Gao C
PLoS One; 2018; 13(8):e0202269. PubMed ID: 30125322
[TBL] [Abstract][Full Text] [Related]
38. Effects of once-yearly zoledronic acid on bone density and incident vertebral fractures in nonmetastatic castration-sensitive prostate cancer patients with osteoporosis.
Watanabe D; Kimura T; Watanabe K; Takano H; Uehara Y; Minowa T; Yamashita A; Yoshikawa S; Mizushima A
BMC Cancer; 2021 Apr; 21(1):422. PubMed ID: 33863312
[TBL] [Abstract][Full Text] [Related]
39. Relationship between pretreatment rate of bone loss and bone density response to once-yearly ZOL: HORIZON-PFT extension study.
Eastell R; Boonen S; Cosman F; Reid IR; Palermo L; Cummings SR; Black DM
J Bone Miner Res; 2015 Mar; 30(3):570-4. PubMed ID: 25214069
[TBL] [Abstract][Full Text] [Related]
40. Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates.
Miller PD; Pannacciulli N; Brown JP; Czerwinski E; Nedergaard BS; Bolognese MA; Malouf J; Bone HG; Reginster JY; Singer A; Wang C; Wagman RB; Cummings SR
J Clin Endocrinol Metab; 2016 Aug; 101(8):3163-70. PubMed ID: 27270237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
